In a quiet corner of Austin, scientists at the University of Minnesota’s Hormel Institute have been zooming in on polio at nearly the atomic scale and finding its soft spots. Their work helped map exactly how human antibodies grab onto poliovirus capsids, a result researchers say could open the door to a new class of antiviral drugs. By resolving structures of antibody-virus complexes in great detail and tracking the precise capsid contacts that shut infection down, the team is giving drug developers sharper targets for future biologic treatments.
High-resolution maps reveal how antibodies block the virus
The study, published in Nature Communications, leans on cryo-electron microscopy to reconstruct four different poliovirus-antibody complexes at near-atomic resolution. The researchers report that several human antibodies cluster around the capsid’s five-fold “canyon” region and overlap the normal poliovirus receptor-binding site, which likely keeps the virus from slipping into human cells. Those conserved contact points, the paper notes, effectively serve as blueprints for designing antiviral biologics that aim for the very same spots.
Hormel Institute’s cryo-EM work in Austin
On the Austin side of the collaboration, scientists at the Hormel Institute supplied key datasets collected on the institute’s Titan Krios cryo-EM system and are listed among the paper’s co-authors, according to the institute’s news office. In its coverage, the release casts the findings as a local win for Austin’s high-end imaging infrastructure and emphasizes that the new structural maps are poised to feed into rational drug-design efforts. The Hormel Institute lays out its role in the project.
Researchers call the antibodies templates for therapeutics
Lead author Benjamin Waddey told local reporters that the antibodies uncovered in the study "can serve as templates for rational design of therapeutics against poliovirus." Susan Hafenstein of the Hormel Institute added that the antibodies "have shown neutralizing effects across all three serotypes" and said that developing actual antiviral treatments is the crucial next step, according to local coverage. As KIMT reports, the team views these structural templates as a way to speed up the long grind of therapeutics development.
Why the work matters now
Globally, wild poliovirus cases have fallen by more than 99% since the Global Polio Eradication Initiative launched in 1988, yet eradication still is not complete, and circulating vaccine-derived outbreaks continue to surface in some regions, the Global Polio Eradication Initiative notes. At the same time, there are no antiviral drugs that cure polio, and public-health officials stress that vaccines remain the primary line of defense. That treatment gap is exactly what these new antibody maps are meant to help address, according to the Hormel Institute’s release, which also underscores how few therapeutic options exist today. The Hormel Institute specifically highlights the absence of current treatment choices.
Which antibodies could become drugs
The paper focuses on a cross-neutralizing antibody class that reaches conserved residues deep in the canyon, along with another candidate, 10D2, that neutralizes serotypes 2 and 3. Those traits, the authors argue, make these antibodies attractive starting points for biologic drugs. The structural analyses further suggest that if the virus tried to mutate away from canyon-binding antibodies, it would likely disrupt receptor binding at the same time, making resistance harder to pull off and boosting the appeal of targeting that region. Nature Communications contains the full models and analyses for those interactions.
For now, public-health authorities continue to emphasize that vaccination is the best protection against polio, while researchers frame the new antibody blueprints as a potential second line of defense if future clinical development pans out. The findings also underline how a relatively small Austin-based team is plugged into the international push to finally close the remaining polio eradication gap. For vaccine and surveillance policy, the Global Polio Eradication Initiative guidance remains the primary reference.
